keytruda
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
July 29, 2024Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
May 29, 2024Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda
Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
Merck shares data from phase 3 trial of Keytruda for gastric cancers
May 2, 2024Research and Development Gastric, MSD, Merck, Oncology, keytruda
Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
April 10, 2024Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …
Merck shares results for Keytruda in cervical cancer treatment
March 18, 2024Research and Development Merck, Oncology, cervical cancer, keytruda, women's health
Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, …
FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment
January 15, 2024Medical Communications FDA, Oncology, cervical cancer, keytruda
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
FDA approves Merck’s Keytruda for gastric cancer treatment
November 17, 2023Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda
Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …
Merck’s Keytruda approved by EC for gastric cancer
August 30, 2023Research and Development EC, Merck, Oncology, gastric cancer, keytruda
Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …
Merck shares data from phase 3 trial for breast cancer treatment
August 1, 2023Research and Development MSD, Merck, Oncology, breast cancer, keytruda
Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …
NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
October 22, 2020Sales and Marketing MSD, NCIE, NHS, keytruda
NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …
Positive five-year Keytruda survival data revealed at ESMO in metastatic, PD-L1+ non-small cell lung cancer
September 22, 2020Manufacturing and Production, Research and Development ESMO 2020, MSD, keytruda, pharma
MSD took the opportunity at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to unveil new Phase 3 …
New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020
September 21, 2020Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda
New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …
MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations
May 29, 2020Medical Communications, Research and Development Lenvima, keytruda, pharma
MSD has pulled back the curtain on new data from two trials of its anti-PD-1 immunotherapy Keytruda (pemvbrolizmuab) in combination …
MSD’s Keytruda hits Phase 3 main goal in first-line colorectal cancer sub-population
April 3, 2020Medical Communications, Research and Development MSD, colorectal cancer, keytruda, pharma
MSD has lifted the veil on new Phase 3 for its blockbuster immunotherapy Keytruda, showing that the anti-PD-1 therapy met …
Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund
March 12, 2020Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …
